Takara Bio Inc. provided earnings guidance for the six months ending September 30, 2021. For the six months, the company expects net sales of JPY 24,609 million, operating profit of JPY 7,139 million, net income attributable to owners of the parent of JPY 4,889 million or JPY 40.61 per share. For the year ending March 31, 2022, the company expects net sales of JPY 50,500 million, operating profit of JPY 14,000 million, net income attributable to owners of the parent of JPY 9,800 million or JPY 81.38 per share.